Eton Pharmaceutcials, Inc. Common Stock
ETONEton Pharmaceuticals, Inc. (ETON) is a specialty pharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. It aims to provide innovative solutions for underserved patient populations through the development of injectable, oral, and topical formulations. The company leverages its expertise in formulation development and regulatory affairs to bring new treatments to market.
Company News
Eton Pharmaceuticals announced the acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution from Pierre Fabre Medicament. HEMANGEOL is the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy. The acquisition marks Eton's achievement of ten commercial products and is expecte...
Eton Pharmaceuticals announced FDA approval of DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus treatment. The product, launching March 9th, is the first FDA-approved oral liquid formulation enabling precise dosing without tablet splitting. Eton projects peak annual sales of $30-50 million with patent protection through...
•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life S...
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 -
